Laura Pazzaglia

Summary

Affiliation: Istituti Ortopedici Rizzoli
Country: Italy

Publications

  1. ncbi Differential gene expression in classic giant cell tumours of bone: Tenascin C as biological risk factor for local relapses and metastases
    Laura Pazzaglia
    Laboratory of Experimental Oncology, Istituto Ortopedico Rizzoli, University of Bologna, Bologna, Italy
    Histopathology 57:59-72. 2010
  2. ncbi Genetic and molecular alterations in rhabdomyosarcoma: mRNA overexpression of MCL1 and MAP2K4 genes
    L Pazzaglia
    Laboratory of Oncologic Research, Rizzoli Orthopaedic Institute, Bologna, Italy
    Histol Histopathol 24:61-7. 2009
  3. ncbi Role of MMP-9 and its tissue inhibitor TIMP-1 in human osteosarcoma: findings in 42 patients followed for 1-16 years
    Cristina Ferrari
    Laboratory of Oncologic Research, Rizzoli Orthopaedic Institute, Bologna, Italy
    Acta Orthop Scand 75:487-91. 2004
  4. ncbi Identification of potential biomarkers for giant cell tumor of bone using comparative proteomics analysis
    Amalia Conti
    Laboratory of Experimental Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy
    Am J Pathol 178:88-97. 2011
  5. ncbi miRNA expression profile in human osteosarcoma: role of miR-1 and miR-133b in proliferation and cell cycle control
    Chiara Novello
    Laboratory of Experimental Oncology, Rizzoli Orthopaedic Institute, I 40136 Bologna, Italy
    Int J Oncol 42:667-75. 2013
  6. ncbi NG2 expression predicts the metastasis formation in soft-tissue sarcoma patients
    Maria Serena Benassi
    Laboratory of Oncology Research, Rizzoli Orthopaedic Institute, Bologna, Italy
    J Orthop Res 27:135-40. 2009
  7. ncbi Activation of metalloproteinases-2 and -9 by interleukin-1alpha in S100A4-positive liposarcoma cell line: correlation with cell invasiveness
    Laura Pazzaglia
    Department of Muscoloskeletal Oncology, Rizzoli Orthopaedic Institute, 40100, Bologna, Italy
    Anticancer Res 24:967-72. 2004
  8. ncbi Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells
    Maria Serena Benassi
    Laboratory of Oncologic Research, Rizzoli Orthopaedic Institute, Bologna, Italy
    Cancer Lett 250:194-205. 2007
  9. ncbi Molecular alterations of monophasic synovial sarcoma: loss of chromosome 3p does not alter RASSF1 and MLH1 transcriptional activity
    L Pazzaglia
    Laboratory of Oncologic Research, Rizzoli Orthopaedic Institute, Bologna, Italy
    Histol Histopathol 21:187-95. 2006
  10. ncbi Identification of markers of possible prognostic value in 57 giant cell tumors of bone
    Gabriella Gamberi
    Laboratory of Oncologic Research, Rizzoli Orthopaedic Institute, I 40136 Bologna, Italy
    Oncol Rep 10:351-6. 2003

Collaborators

Detail Information

Publications15

  1. ncbi Differential gene expression in classic giant cell tumours of bone: Tenascin C as biological risk factor for local relapses and metastases
    Laura Pazzaglia
    Laboratory of Experimental Oncology, Istituto Ortopedico Rizzoli, University of Bologna, Bologna, Italy
    Histopathology 57:59-72. 2010
    ..GCT specimens with different behaviour associated with an increased risk of local and/or distant relapses were studied...
  2. ncbi Genetic and molecular alterations in rhabdomyosarcoma: mRNA overexpression of MCL1 and MAP2K4 genes
    L Pazzaglia
    Laboratory of Oncologic Research, Rizzoli Orthopaedic Institute, Bologna, Italy
    Histol Histopathol 24:61-7. 2009
    ....
  3. ncbi Role of MMP-9 and its tissue inhibitor TIMP-1 in human osteosarcoma: findings in 42 patients followed for 1-16 years
    Cristina Ferrari
    Laboratory of Oncologic Research, Rizzoli Orthopaedic Institute, Bologna, Italy
    Acta Orthop Scand 75:487-91. 2004
    ..The activity of matrix metalloproteinases (MMPs) in degrading extracellular matrix is controlled by activation of proenzymes and inhibition of MMP tissue inhibitors (TIMPs)...
  4. ncbi Identification of potential biomarkers for giant cell tumor of bone using comparative proteomics analysis
    Amalia Conti
    Laboratory of Experimental Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy
    Am J Pathol 178:88-97. 2011
    ....
  5. ncbi miRNA expression profile in human osteosarcoma: role of miR-1 and miR-133b in proliferation and cell cycle control
    Chiara Novello
    Laboratory of Experimental Oncology, Rizzoli Orthopaedic Institute, I 40136 Bologna, Italy
    Int J Oncol 42:667-75. 2013
    ..Our data assessed specific miRNA profiling deregulation in OS clinical samples and suggest that the expression of miR-1 and miR-133b may control cell proliferation and cell cycle through MET protein expression modulation...
  6. ncbi NG2 expression predicts the metastasis formation in soft-tissue sarcoma patients
    Maria Serena Benassi
    Laboratory of Oncology Research, Rizzoli Orthopaedic Institute, Bologna, Italy
    J Orthop Res 27:135-40. 2009
    ....
  7. ncbi Activation of metalloproteinases-2 and -9 by interleukin-1alpha in S100A4-positive liposarcoma cell line: correlation with cell invasiveness
    Laura Pazzaglia
    Department of Muscoloskeletal Oncology, Rizzoli Orthopaedic Institute, 40100, Bologna, Italy
    Anticancer Res 24:967-72. 2004
    ....
  8. ncbi Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells
    Maria Serena Benassi
    Laboratory of Oncologic Research, Rizzoli Orthopaedic Institute, Bologna, Italy
    Cancer Lett 250:194-205. 2007
    ....
  9. ncbi Molecular alterations of monophasic synovial sarcoma: loss of chromosome 3p does not alter RASSF1 and MLH1 transcriptional activity
    L Pazzaglia
    Laboratory of Oncologic Research, Rizzoli Orthopaedic Institute, Bologna, Italy
    Histol Histopathol 21:187-95. 2006
    ..These findings confirm the genetic complexity of monophasic synovial sarcoma and underline the need to integrate different analyses for a better knowledge of this tumour, essential to investigate new diagnostic and prognostic markers...
  10. ncbi Identification of markers of possible prognostic value in 57 giant cell tumors of bone
    Gabriella Gamberi
    Laboratory of Oncologic Research, Rizzoli Orthopaedic Institute, I 40136 Bologna, Italy
    Oncol Rep 10:351-6. 2003
    ..Therefore, the evaluation of the expression levels of these proteins at the time of diagnosis may be taken into consideration for a classification of GCT into categories characterized by a different risk to relapse...
  11. ncbi Altered expression of urokinase-type plasminogen activator and plasminogen activator inhibitor in high-risk soft tissue sarcomas
    M S Benassi
    Laboratory of Oncology Research, Rizzoli Orthopaedic Institute, Bologna, Italy
    Histol Histopathol 22:1017-24. 2007
    ....
  12. ncbi Amplification of CDK4, MDM2, SAS and GLI genes in leiomyosarcoma, alveolar and embryonal rhabdomyosarcoma
    P Ragazzini
    Laboratory of Oncologic Research, Rizzoli Orthopaedic Institute, Bologna, Italy
    Histol Histopathol 19:401-11. 2004
    ..These two seem to have a more similar behavior than anaplastic and classic embryonal that are classified in the same subtype...
  13. ncbi Proteases and interleukin-6 gene analysis in 92 giant cell tumors of bone
    G Gamberi
    Laboratory of Oncologic Research, Department of Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy
    Ann Oncol 15:498-503. 2004
    ..Few prognostic markers have been reported to predict the clinical outcome of GCT patients, so is very important to find the factor that can be implicated in its potential aggressiveness...
  14. ncbi Tissue and serum loss of metalloproteinase inhibitors in high grade soft tissue sarcomas
    M S Benassi
    Oncological Research Laboratory, Istituti Ortopedici Rizzoli, Bologna, Italy
    Histol Histopathol 18:1035-40. 2003
    ..0001). In conclusion, low levels of negative regulators of proteolysis may be related to tumor biological aggressiveness and used to select patients with poor prognosis to improve cure...
  15. ncbi Involvement of INK4A gene products in the pathogenesis and development of human osteosarcoma
    M S Benassi
    Department of Musculoskeletal Oncology, Laboratory of Oncologic Research, Rizzoli Orthopedic Institute, Bologna, Italy
    Cancer 92:3062-7. 2001
    ..It encodes two transcripts, p16 and p14 alternate reading frame (ARF), involved in retinoblastoma protein (pRb)- and p53- cell growth control pathways, respectively...